Blackston Financial Advisory Group LLC Buys 409 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Blackston Financial Advisory Group LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 72.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 972 shares of the medical research company’s stock after purchasing an additional 409 shares during the period. Blackston Financial Advisory Group LLC’s holdings in Thermo Fisher Scientific were worth $601,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TMO. Ballentine Partners LLC grew its position in shares of Thermo Fisher Scientific by 7.0% during the 3rd quarter. Ballentine Partners LLC now owns 8,260 shares of the medical research company’s stock valued at $5,109,000 after acquiring an additional 543 shares during the period. Busey Bank increased its holdings in Thermo Fisher Scientific by 1.0% in the 3rd quarter. Busey Bank now owns 29,187 shares of the medical research company’s stock worth $18,054,000 after acquiring an additional 300 shares in the last quarter. Silver Oak Securities Incorporated lifted its holdings in Thermo Fisher Scientific by 8.5% during the third quarter. Silver Oak Securities Incorporated now owns 693 shares of the medical research company’s stock valued at $429,000 after purchasing an additional 54 shares in the last quarter. Moody Lynn & Lieberson LLC increased its stake in shares of Thermo Fisher Scientific by 10.9% in the third quarter. Moody Lynn & Lieberson LLC now owns 54,977 shares of the medical research company’s stock worth $34,007,000 after purchasing an additional 5,414 shares in the last quarter. Finally, Harbour Trust & Investment Management Co raised its position in shares of Thermo Fisher Scientific by 1.5% during the 3rd quarter. Harbour Trust & Investment Management Co now owns 15,377 shares of the medical research company’s stock valued at $9,512,000 after purchasing an additional 226 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.5 %

NYSE:TMO opened at $560.00 on Friday. The company has a market cap of $213.92 billion, a price-to-earnings ratio of 34.58, a price-to-earnings-growth ratio of 3.75 and a beta of 0.77. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a twelve month low of $420.21 and a twelve month high of $627.88. The stock has a fifty day simple moving average of $607.04 and a 200-day simple moving average of $584.39.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.69 earnings per share. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 6,300 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,548,375.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. Evercore ISI decreased their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday. Bank of America lifted their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Stephens began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective for the company. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.